Free Daily Podcast Summary
BackTable Urology: Daily Summaries Delivered
by BackTable Inc.
The BackTable Urology Podcast is a resource for practicing urologists to learn tips, techniques, and practical advice from their peers in the field. Listen here or on the streaming platform of your choice.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- Yesterday55 min
Ep. 343 Direct Contracting in Healthcare with Mark Cuban
“No cancer patient ever got healthier because their claim was denied and delayed. None. Not one.” Mark Cuban's verdict will ring true for any urologist who has fought a denied or delayed claim, and his alternative is a contract that starts by trusting the doctor. On this episode of BackTable Urology, Dr. Ruchika Talwar, urologic oncologist and value-based care leader, talks with Mark Cuban, entrepreneur and founder of Mark Cuban Cost Plus Drug Company, about who actually sets the price of care in the United States. They trace how a cold email about drug shortages led to Cost Plus Drugs and then Cost Plus Wellness, an open source library of direct contracts between self-insured employers and providers, and why he believes the contract, not the published price, is where the real problems hide. By his estimate, 67% of people with job-based coverage get it through a self-insured employer, which makes employers, not insurers, the real payers in American healthcare. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps00:00 - Introduction01:53 - From Drug Shortages to Cost Plus Drugs06:08 - Cost Plus Wellness and Direct Contracts11:04 - Publishing Provider Contracts16:39 - Using AI to Review Contracts and RFPs20:16 - Direct Contracting Advice for Hospitals and Physicians26:33 - Value-Based Care, Brokers, and Self-Insured Hospitals32:09 - Direct Contracting for Independent Practices34:20 - AI as a Business Adviser for Physicians38:39 - National Policy and Who Pays for Healthcare46:59 - Misaligned Incentives and Corporate Culture51:00 - Key Takeaways54:04 - Closing Remarks --- More about this episodeThe conversation then turns practical for physicians. Mark Cuban lays out how hospitals, clinics, and independent practices can find the self-insured employers among their own patients and offer direct contracts or carve-outs, why a promise to trust the doctor can earn employers a better rate, and how he runs contracts that stretch past a thousand pages through several AI models in turn. He and Dr. Talwar also cover what employers can learn from Form 5500 filings, the national changes he would make, from ending gag clauses to standardized public contracts, and why both see misaligned incentives as the root of the problem. --- ResourcesMark Cuban Cost Plus Drug Companyhttps://costplusdrugs.com Cost Plus Wellness: an open source initiative by Mark Cubanhttps://costpluswellness.com Mark Cuban dives into direct contracting. Becker's Hospital Review. 2026https://www.beckershospitalreview.com/finance/mark-cuban-dives-into-direct-hospital-contracting/ Form 5500 filings search (EFAST2), U.S. Department of Laborhttps://www.efast.dol.gov/welcome.html KFF. 2025 Employer Health Benefits Surveyhttps://www.kff.org/health-costs/2025-employer-health-benefits-survey/ Gag Clause Prohibition Compliance Attestation. Centers for Medicare & Medicaid Serviceshttps://www.cms.gov/marketplace/about/oversight/other-insurance-protections/gag-clause-prohibition-compliance-attestation New generic drug company named after Mark Cuban first founded by a part-time radiologist. Health Imaginghttps://healthimaging.com/topics/healthcare-management/medical-practice-management/mark-cuban-generic-drug-company Dr. Ruchika Talwar, BackTable Urology contributor pagehttps://www.backtable.com/shows/urology/contributors/dr-ruchika-talwar ---BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.► https://www.backtable.com/app
- 3 days ago35 min
Ep. 342 Mid-Career Urology: Understanding Career Evolution & Challenges with Dr. Debra Fromer and Dr. Anne Suskind
Mid-career is the stretch when you are no longer the new person on the block, but not yet the one in charge, and it gets far less attention than the years on either side of it. On this episode of BackTable Urology, presented in collaboration with the Society of Women in Urology (SWIU), Dr. Michelle Van Kuiken talks with Dr. Debra Fromer and Dr. Anne Suskind, both urology division chiefs and faculty vice chairs, about what no one tells you about mid-career. They describe how to know you have arrived there, why boredom can be the clearest signal that it is time to change, and why mid-career is the moment to say yes to a leadership role you have never trained for, even if what you learn is that you do not like it. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast was developed in collaboration with Society of Women in Urologyhttps://swiu.org/home.aspx --- Timestamps 00:00 - Introduction01:50 - Defining Mid-Career04:05 - Career as an Evolution07:21 - Plateaus, Boredom, and Burnout09:55 - Imposter Syndrome and New Leadership Roles11:37 - Traps That Stall Mid-Career Growth15:14 - Changing Expectations at Work and at Home18:17 - Redefining Success20:51 - Mentorship at Every Career Stage22:26 - Phasing Out and Legacy25:11 - Staying Motivated27:38 - Life Outside Work31:10 - Parting Words and Closing Remarks --- More about this episode The three surgeons then name the traps that stall growth, from support that falls away after the junior years to unrecognized, unpaid roles and the competing demands of young children and aging parents. Dr. Fromer explains why control over her own time has always been her measure of success, and Dr. Suskind makes the case for new mentors and peer mentors at every stage. They close on phasing out and legacy, what keeps them motivated, and how challenges outside the hospital, from leading a urology Battle of the Bands to tournament golf, can feed a career. --- Resources Society of Women in Urology (SWIU)https://www.swiu.org New York Section of the American Urological Associationhttps://www.nyaua.com Docs Who Rock Raise More than $10,000 for Important Urological Initiatives. HMH Maestro, 2025https://hmhmaestro.org/en/topics/featured-physicians/2025/04/21/docs-who-rock-raise-more-than-10000-for-important-urological-initiatives Dr. Michelle Van Kuiken, BackTable Urology contributor pagehttps://www.backtable.com/shows/urology/contributors/dr-michelle-van-kuiken --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app
- 1 weeks ago40 min
Ep. 341 Understanding Overactive Bladder in Male Patients with Dr. Bilal Chughtai
How many prostate medications and procedures should a man try before anyone checks his bladder? Dr. Bilal Chughtai has met men who worked through an alpha blocker, add-on medications, a minimally invasive prostate procedure, and even resective surgery before anyone named overactive bladder as part of the problem. On this episode of BackTable Urology, Dr. Anjali Kapur, urogynecologist at Hackensack Meridian Health, welcomes Dr. Chughtai, chief of urology at Northwell Health's Plainview and Syosset hospitals, to rethink how urologists separate overactive bladder (OAB) from benign prostatic hyperplasia (BPH) in men. Dr. Chughtai explains how he reads the storage and voiding items of the International Prostate Symptom Score (IPSS), why he usually starts with a beta-3 agonist rather than an anticholinergic, how he trims polypharmacy one medication holiday at a time, and when urodynamics helps decide whether to treat the prostate, the bladder, or both. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by Sumitomo Pharma America, Inc.https://www.us.sumitomo-pharma.com/ --- Timestamps 00:00 - Introduction02:37 - Initial Evaluation and First-Line Therapy06:11 - Combination Therapy and Medication Holidays09:37 - Reassessing Symptoms After an Outlet Procedure11:59 - Botox and Neuromodulation in Men15:14 - Persistent Symptoms After Prior BPH Treatment18:44 - The COURAGE Trial and Urge Incontinence23:22 - Combining Therapies and Setting Goals25:48 - Questionnaires, Bladder Diaries, and Underreporting29:05 - OAB Awareness in Primary Care31:14 - Nocturia and Sleep Apnea33:23 - Timing of Intervention and Bladder Health38:04 - Final Takeaways and Closing Remarks --- More about this episode The two then turn to third-line therapy in men, including intradetrusor botulinum toxin, sacral neuromodulation, and tibial nerve stimulation, and to men whose storage symptoms persist or appear after an outlet procedure. Dr. Chughtai shares what the COURAGE trial of a beta-3 agonist added to BPH therapy taught him about asking men directly about urge incontinence, along with his goal of a 50% improvement in symptoms, the limits of questionnaires and bladder diaries, his research on OAB awareness in primary care, and the link between nocturia and sleep apnea. They close on the open question of when to treat the bladder before it changes, and why counseling should inform men without threatening them. --- Resources Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial. J Urol. 2024https://pubmed.ncbi.nlm.nih.gov/38708869/ Vibegron for overactive bladder in men with benign prostatic hyperplasia/obstruction: insights from the COURAGE trial. Transl Androl Urol. 2025https://pubmed.ncbi.nlm.nih.gov/40376518/ Lower Urinary Tract Symptoms Following Transurethral Resection of Prostate. Curr Urol Rep. 2018https://pubmed.ncbi.nlm.nih.gov/30128964/ 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol. 1998https://pubmed.ncbi.nlm.nih.gov/9628595/ The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladderhttps://www.auanet.org/guidelines-and-quality/guidelines/idiopathic-overactive-bladder BackTable Urology Episode 138: Hood-Sparing & Greenlight Laser Therapy in BPH Managementhttps://www.backtable.com/shows/urology/podcasts/138/hood-sparing-greenlight-laser-therapy-in-bph-management Dr. Bilal Chughtai, BackTable Urology contributor pagehttps://www.backtable.com/shows/urology/contributors/dr-bilal-chughtai Dr. Anjali Kapur, BackTable Urology contributor pagehttps://www.backtable.com/shows/urology/contributors/dr-anjali-kapur --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app
- 1 weeks ago43 min
Ep. 340 Understanding Intermediate-Risk Bladder Cancer with Dr. Wesley Yip
By one estimate, half or more of all non-muscle invasive bladder cancer (NMIBC) is intermediate risk, yet the major guidelines still do not define it the same way, which leaves urologists sorting a large, mixed group of patients without a shared playbook for when to resect again, treat in the office, or start intravesical therapy. On this episode of BackTable Urology, Dr. Ruchika Talwar welcomes Dr. Wesley Yip, urologic oncologist at City of Hope, to rethink what she calls the forgotten stepchild of bladder cancer: intermediate-risk non-muscle invasive bladder cancer (NMIBC). Dr. Yip explains why he sees the category as a catch-all rather than a single biological entity, by his estimate covering 50 to 60 percent of NMIBC, why he now relies on the International Bladder Cancer Group (IBCG) definition, and why tumor grade comes first, ahead of multiplicity, size, and recurrence timing. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction02:24 - Defining Intermediate-Risk NMIBC07:53 - Case Presentation and the Initial TURBT10:42 - Evaluating the First Recurrence13:09 - High-Grade Cytology and Blue Light Cystoscopy15:01 - The Burden of Repeat TURBT16:57 - Office Fulguration and Chemoablation20:23 - Chemoablation Tolerability and Patient Selection24:24 - Intravesical Chemotherapy and Treatment Barriers28:08 - New Formulations and Upcoming Trials33:12 - Recurrence After Chemoablation and De-escalation38:00 - Future Directions and Patient-Centered Endpoints42:39 - Closing Remarks --- More about this episode Working through the case of a healthy 67-year-old man with recurrent low-grade Ta disease, the two discuss what to document at the first resection, how to counsel patients, when to return to the operating room, and when office fulguration, intravesical chemoablation, or intravesical chemotherapy with gemcitabine and docetaxel makes more sense. They cover the cumulative burden of repeat transurethral resection, practical lessons from bringing chemoablation into the clinic, how to read new trial data, and when to de-escalate surveillance. Dr. Yip closes with his hopes for the next five years: a biology-based definition and trials that measure fewer recurrences, fewer procedures, and better quality of life. --- Resources Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. Eur Urol Oncol. 2022https://pubmed.ncbi.nlm.nih.gov/35718695/ Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group. Eur Urol Oncol. 2025https://pubmed.ncbi.nlm.nih.gov/41076366/ All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta Tumors. J Urol. 2022https://pubmed.ncbi.nlm.nih.gov/35770498/ Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guidelinehttps://www.auanet.org/guidelines-and-quality/guidelines/bladder-cancer-non-muscle-invasive-guideline EAU Guidelines on Non-muscle-invasive Bladder Cancerhttps://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer Bladder Cancer Advocacy Network (BCAN)https://bcan.org Dr. Wesley Yip, City of Hope physician profilehttps://www.cancercenter.com/physician-directory/wesley-yip Dr. Ruchika Talwar, BackTable Urology contributor pagehttps://www.backtable.com/shows/urology/contributors/dr-ruchika-talwar --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app
- 2 weeks ago58 min
Ep. 339 AI's Role in Enhancing Urology Care with Dr. David Canes
By his own estimate, an AI scribe gives one urologist about two hours of his day back, and an evidence tool built into it has taught him something new in the clinic almost every day. On this episode of BackTable Urology, Dr. Ruchika Talwar welcomes back Dr. David Canes, urologist at Lahey Hospital & Medical Center and founder of WellPrept, to talk about how urologists can practically put AI to work. Dr. Canes explains why he sees this moment as a renaissance for physicians, how an AI scribe turned him from author into proofreader, by his estimate saving about two hours a day, and why evidence tools running alongside the scribe now answer questions in the exam room, including a question about post-prostatectomy dysorgasmia, a complaint that rarely comes up in clinic. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction03:32 - Getting Started With AI in Practice07:24 - AI Scribes and Cognitive Load14:18 - AI Evidence Tools at the Point of Care18:41 - Context, Pre-Charting, and Evidence in the Exam Room24:52 - AI for Email and Personal Workflow29:09 - Building a Permanent AI Memory34:20 - AI Skepticism, Privacy, and Intellectual Honesty40:47 - Will AI Replace Physicians?46:39 - Pre-Charting, Patient Education, and Care Journeys49:27 - Reducing the In-Basket Burden53:04 - Where to Start With AI55:27 - Closing Remarks --- More about this episode The conversation then moves beyond the clinic. Dr. Canes describes an AI layer on email that flags what cannot wait, and a permanent AI memory built from plain text files that keeps research, licenses, talks, and family life organized, with a firm rule that no protected health information goes anywhere without a business associate agreement. He and Dr. Talwar discuss what work is worth delegating to AI, push back on a recent JAMA perspective arguing that autonomous AI may outperform physicians, and run through tools for pre-charting, patient education, postoperative care journeys, and front-desk calls. Dr. Canes closes with simple advice for exhausted physicians: ask the AI you already use to build you a 90-day plan. --- Resources Will Autonomous AI Exceed AI-Aided Physicians as the Best Medical Care? JAMA. 2026https://jamanetwork.com/journals/jama/fullarticle/2852952 The utility of tamsulosin in the management of orgasm-associated pain: a pilot analysis. Eur Urol. 2005https://pubmed.ncbi.nlm.nih.gov/15716202/ WellPrepthttps://www.wellprept.com BackTable Urology Episode 55: Patient Preparation Made Easy: The WellPrept Storyhttps://www.backtable.com/shows/urology/podcasts/55/patient-preparation-made-easy-the-wellprept-story Dr. David Canes, BackTable Urology contributor pagehttps://www.backtable.com/shows/urology/contributors/dr-david-canes Dr. Ruchika Talwar, BackTable Urology contributor pagehttps://www.backtable.com/shows/urology/contributors/dr-ruchika-talwar --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app
- 2 weeks ago48 min
Ep. 338 From Numbers to Decisions: Clinical Utility of Biomarkers in Prostate Cancer Diagnosis with Dr. Amir Lebastchi
Every prostate cancer biomarker returns a number, but the real question is whether that number changes what you do next for the patient. On this episode of BackTable Urology, Dr. Ruchika Talwar welcomes Dr. Amir Lebastchi, urologic oncologist at Keck Medicine of USC, to discuss how biomarkers are moving prostate cancer care from numbers to meaningful clinical decisions. They define what makes a biomarker clinically useful, organize the growing list of blood, urine, and tissue tests into pre-biopsy, post-negative-biopsy, and post-diagnosis settings, and talk through where these tests fit alongside MRI after an elevated PSA. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by Cleveland Diagnosticshttps://www.isopsa.com/ --- Timestamps 00:00 - Introduction02:59 - Clinical Utility and a Framework for Biomarkers08:43 - Workup of an Elevated PSA11:42 - Pre-Biopsy Blood and Urine Tests13:29 - Equivocal MRI, Outside Imaging, and Community Practice20:26 - Patient Factors and Practical Considerations24:44 - Case: Elevated PSA and a Negative MRI30:11 - Case: Biopsy Approach and Discordant Results34:41 - Counseling on PSA Limitations and Overdiagnosis37:05 - Biomarkers in Active Surveillance and Renaming Grade Group 140:56 - AI and the Future of Biomarkers44:38 - Take-Home Points and Closing Remarks --- More about this episode The discussion covers equivocal MRI findings, patient counseling, and the practical impact of age, family history, and race when interpreting PSA levels. Through real cases, Dr. Lebastchi explains when he repeats a PSA, how he performs a templated transperineal biopsy, and why a negative MRI plus a negative biomarker can give him the confidence to forgo a biopsy. They also touch on active surveillance, the debate over renaming grade group 1 prostate cancer, and how AI may help future tests guide treatment intensity rather than just risk category. Dr. Lebastchi closes with the clinician’s obligation to know all available tests and use those that truly inform management. --- Resources Early Detection of Prostate Cancer: AUA/SUO Guideline (2023)https://www.auanet.org/guidelines-and-quality/guidelines/early-detection-of-prostate-cancer-guidelines Clinical validation of IsoPSA, a single parameter, structure-focused assay for improved detection of prostate cancer: A prospective, multicenter study. Urol Oncol. 2022https://pubmed.ncbi.nlm.nih.gov/35840465/ Using IsoPSA With Prostate Imaging Reporting and Data System Score May Help Refine Biopsy Decision Making in Patients With Elevated PSA. Urology. 2023https://pubmed.ncbi.nlm.nih.gov/36965817/ Low-Grade Prostate Cancer: Time to Stop Calling It Cancer. J Clin Oncol. 2022https://pubmed.ncbi.nlm.nih.gov/35436144/ The influence of the "cancer" label on perceptions and management decisions for low-grade prostate cancer. J Natl Cancer Inst. 2023https://pubmed.ncbi.nlm.nih.gov/37285311/ Dr. Amir Lebastchi, Keck Medicine of USC physician profilehttps://keckmedicine.org/provider/amir-h-lebastchi Dr. Ruchika Talwar, BackTable Urology contributor pagehttps://www.backtable.com/shows/urology/contributors/dr-ruchika-talwar --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app
- 3 weeks ago25 min
Ep. 337 Advancements in Ureteroscopy for Stone Management with Dr. Karen Stern
How is suction technology changing what it means to be “stone-free” after ureteroscopy? On this episode of BackTable Urology, Dr. Ruchika Talwar welcomes Dr. Karen Stern, endourologist at Mayo Clinic Arizona, for a practical discussion of how ureteroscopy is evolving in the era of suction. They discuss how thin-slice CT has revealed just how much stone typically remains after surgery, why dusting versus fragmenting is now a patient-dependent choice, and what to consider when selecting between suction sheaths, aspiration scopes, and traditional access. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by Dornierhttps://www.dornier.com/backtable --- Timestamps 00:00 - Introduction02:16 - Residual Stone and Defining Success04:59 - Dusting, Fragmentation and Suction Devices07:15 - Patient Selection, OR Setup and Laser Settings11:39 - Evidence, Stone Clearance and Infection Risk15:39 - Community Adoption and Technique Pearls20:05 - Integrated Systems and Artificial Intelligence22:29 - Take-Home Points and Closing Remarks --- More about this episode The doctors discuss patient selection, OR setup, stenting, and why stones over a centimeter benefit most from a suction approach. Dr. Stern shares her tips for suction device setup, irrigation and suction settings, and how even a short learning curve can make these techniques routine. They review infection risks, evidence on residual stone volume, pearls for community adoption, and look ahead to integrated laser-suction platforms and AI tools that may one day help define when a case is truly finished. Dr. Karen Stern closes with advice for urologists on the fence: every technology works, but the best choice is the one that fits your practice. --- Resources Are We Overreporting Post-Op Sepsis? The Difference Between Reported and Verified Rates of Post-Ureteroscopy Sepsis Using the Sepsis 3 Criteria at a Single Institution. J Endourol. 2026https://doi.org/10.1177/08927790251394736 Flexible Ureteroscopy with a Flexible and Navigable Suction Ureteral Access Sheath Versus Mini-Percutaneous Nephrolithotomy for Treatment of 2-3 cm Renal Stones: An International, Multicenter, Randomized, Noninferiority Trial. Eur Urol. 2026https://doi.org/10.1016/j.eururo.2025.06.001 Dr. Karen Stern, Mayo Clinic physician profilehttps://www.mayoclinic.org/biographies/stern-karen-l-m-d/bio-20464490 Dr. Ruchika Talwar, BackTable Urology contributor pagehttps://www.backtable.com/shows/urology/contributors/dr-ruchika-talwar --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app
- 4 weeks ago47 min
Ep. 336 Biomarkers in Treatment Intensification for Prostate Cancer with Dr. Angela Jia
Same risk group, very different benefit. Can biomarkers help identify who needs treatment intensification in prostate cancer? On this episode of BackTable Urology, Dr. Ruchika Talwar and Dr. Angela Jia, a radiation oncologist at University Hospitals Cleveland Medical Center, break down the difference between prognostic and predictive biomarkers and how genomic testing is informing the way clinicians counsel patients. They review trial data suggesting that men with a low genomic score may gain little from adding hormone therapy, along with early prospective evidence that the luminal B subtype may help identify who benefits most from intensification. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by Verasytehttps://www.veracyte.com/ --- Timestamps 00:00 - Introduction02:08 - Prognostic vs. Predictive Biomarkers06:34 - The NRG/RTOG 0815 Biomarker Cohort10:15 - Applying a Low Genomic Score in Clinic15:16 - Genomic Classifiers After Prostatectomy18:52 - RTOG 9601, SPPORT and the Salvage Evidence24:39 - Stage Migration and the Case for an ARPI28:13 - Ordering and Reading the Genomic Report34:31 - Common Mistakes in Interpretation37:31 - Where Genomics Could Go Next41:03 - Reflex Testing, EMR Integration and AI44:44 - Closing Remarks --- More about this episode The conversation covers practical application of test results, counseling with absolute risk numbers, and the pitfalls of stretching predictive claims beyond their evidence. Dr. Jia explains the limits of biopsy sampling, how stage migration with advanced imaging may shift baseline risk, and why a large portion of the genomic score remains unexplained by standard variables. The episode closes with a look at reflex testing, the potential role of AI, and the longer-term goal of giving patients clear, individualized benefit estimates for each treatment option. --- Resources NRG/RTOG 0815: A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer (trial record)https://clinicaltrials.gov/study/NCT00936390 NRG-GU006 (BALANCE): A Phase II Randomized Trial of Salvage Radiotherapy With or Without Apalutamide in Recurrent Prostate Cancer (trial record)https://clinicaltrials.gov/study/NCT03371719 Feng FY, et al. Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. JAMA Oncol. 2021https://pubmed.ncbi.nlm.nih.gov/33570548/ Pollack A, et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT). Lancet. 2022https://pubmed.ncbi.nlm.nih.gov/35569466/ Zhao SG, et al. Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncol. 2017https://pubmed.ncbi.nlm.nih.gov/28494073/ Patel KR, Nguyen PL, et al. Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413 and 9902 Phase 3 Trials. Eur Urol Oncol. 2026https://pubmed.ncbi.nlm.nih.gov/39542826/ Grist E, et al. Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers (STAMPEDE). Cell. 2025https://pubmed.ncbi.nlm.nih.gov/40865526/ Jia AY, et al. Cross-Comparison Individual Patient-Level Analysis of Three Gene Expression Signatures in Localized Prostate Cancer in Over 50,000 Men. JCO Precis Oncol. 2025https://pubmed.ncbi.nlm.nih.gov/40479622/ Dr. Angela Jia, University Hospitals physician profilehttps://www.uhhospitals.org/doctors/Jia-Angela-1902338718 Dr. Ruchika Talwar, BackTable Urology contributor pagehttps://www.backtable.com/shows/urology/contributors/dr-ruchika-talwar --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app
Get BackTable Urology summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Listeners also like.
The Curbsiders Internal Medicine Podcast
Expert-led internal medicine discussions with clinical insights and humor for primary care and hospital medicine providers.
Red Pill Your Healthcast
Two healthcare providers discuss overlooked health issues and empower listeners to make informed decisions for their families.
Treated with Dr. Sara Szal
Dr. Sara Szal explores holistic health solutions through conversations with experts and patients seeking mind, body, and soul healing.
The Peter Attia Drive
Conversations with experts on health, longevity, performance, and critical thinking led by physician Peter Attia.
Extend Podcast with Darshan Shah, MD
Explores science-backed strategies and expert insights to extend healthspan and optimize longevity through actionable health protocols.
Psychiatry & Psychotherapy Podcast
Explores psychiatry and psychotherapy through interviews with experts, trainees, and individuals sharing lived mental health experiences.
Private Practice Playbook
Provides strategies for private practitioners to grow their medical or dental practices and increase profitability.
Get Better Faster
Doctors and researchers discuss functional medicine and root-cause approaches to chronic illness and health optimization.
Bred To Lead
Leadership is developed through real-world turnarounds, early warning signs, and people-first habits that prevent organizational decline.
JOSPT Insights
JOSPT
unPAUSED with Dr. Mary Claire Haver
A board-certified OB-GYN hosts candid discussions with experts and leaders on women's health, identity, and empowerment in midlife.
INTERLUDE: Cancer Stories with Dr. Teplinsky
Eleonora Teplinsky
About BackTable Urology
The BackTable Urology Podcast is a resource for practicing urologists to learn tips, techniques, and practical advice from their peers in the field. Listen here or on the streaming platform of your choice.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from BackTable Urology in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's BackTable Urology daily summary?
It's a free AI-powered email that summarizes new episodes of BackTable Urology as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the BackTable Urology podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official BackTable Urology product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by BackTable Inc..
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts, any in the catalog. Basic raises that to 15, Pro to 40 and Max to 100. Browse our full catalog at /podcasts.
How often does BackTable Urology release new episodes?
BackTable Urology publishes weekly. Our AI generates a summary within hours of each new episode.
What topics does BackTable Urology cover?
BackTable Urology covers topics including Education, Medicine, Fitness, Health & Fitness. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting BackTable Urology summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.